CNC
Centene Corporation NYSE$52.97
Pre-mkt
$52.50
-0.88%
Mkt Cap $26.2B
52w Low $25.08
71.4% of range
52w High $64.15
50d MA $39.50
200d MA $36.86
P/E (TTM)
-3.9x
EV/EBITDA
-4.1x
P/B
1.3x
Debt/Equity
0.9x
ROE
-30.1%
P/FCF
4.7x
RSI (14)
—
ATR (14)
—
Beta
0.59
50d MA
$39.50
200d MA
$36.86
Avg Volume
6.7M
About
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medi…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 2.23 | 3.37 | +51.1% | 49.57 | +2.0% | +8.9% | +8.3% | +7.6% | +8.0% | +6.9% | — |
| Feb 6, 2026 | TNS | -1.22 | -1.19 | +2.5% | 38.46 | -0.1% | -1.1% | +3.0% | +5.1% | +1.9% | +5.5% | — |
| Oct 29, 2025 | TNS | -0.14 | 0.50 | +445.4% | 37.34 | -1.6% | -6.2% | -5.3% | -7.6% | -3.3% | -1.3% | — |
| Jul 25, 2025 | TNS | 0.11 | -0.16 | -243.4% | 28.39 | -0.8% | -5.4% | -10.1% | -9.2% | -8.2% | -8.7% | — |
| Apr 25, 2025 | TNS | 2.52 | 2.90 | +15.1% | 57.69 | +0.5% | +3.1% | +2.7% | +3.7% | +3.0% | +4.3% | — |
| Feb 4, 2025 | TNS | 0.44 | 0.80 | +81.8% | 61.29 | -0.6% | -0.9% | -4.3% | -3.8% | -3.9% | -6.4% | — |
| Oct 25, 2024 | TNS | 1.33 | 1.62 | +21.8% | 64.22 | -0.9% | -4.0% | -5.6% | -3.8% | -3.1% | -1.1% | — |
| Jul 26, 2024 | TNS | 2.07 | 2.42 | +16.9% | 73.10 | +0.4% | +0.5% | +5.5% | +5.2% | +6.6% | +6.8% | — |
| Apr 26, 2024 | TNS | 2.08 | 2.26 | +8.7% | 74.00 | +0.5% | -0.2% | -1.3% | -2.4% | +0.4% | +1.1% | — |
| Feb 6, 2024 | TNS | 0.43 | 0.45 | +4.7% | 74.92 | +0.1% | +0.0% | +2.1% | +3.2% | +4.0% | +2.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Barclays | Maintains | Overweight → Overweight | — | $49.57 | $50.58 | +2.0% | +8.9% | +8.3% | +7.6% | — | — |
| Apr 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $49.57 | $50.58 | +2.0% | +8.9% | +8.3% | +7.6% | — | — |
| Apr 29 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $60 | $49.57 | $50.58 | +2.0% | +8.9% | +8.3% | +7.6% | — | — |
| Apr 29 | UBS | Maintains | Neutral → Neutral | — | $49.57 | $50.58 | +2.0% | +8.9% | +8.3% | +7.6% | — | — |
| Apr 29 | Truist | Maintains | Buy → Buy | — | $49.57 | $50.58 | +2.0% | +8.9% | +8.3% | +7.6% | — | — |
| Apr 29 | BofA Securities | Upgrade | Underperform → Buy | $60 | $49.57 | $50.58 | +2.0% | +8.9% | +8.3% | +7.6% | — | — |
| Apr 20 | Jefferies | Maintains | Hold → Hold | — | $38.17 | $38.41 | +0.6% | +0.4% | +2.5% | +2.0% | +7.7% | +9.6% |
| Mar 19 | JP Morgan | Maintains | Neutral → Neutral | — | $36.16 | $36.14 | -0.1% | -1.6% | -4.9% | -9.3% | -8.8% | -9.5% |
| Mar 11 | Mizuho | Maintains | Neutral → Neutral | — | $36.40 | $36.31 | -0.2% | -1.5% | -5.0% | -5.4% | -4.5% | -4.0% |
| Mar 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $43.82 | $44.16 | +0.8% | +2.7% | -1.3% | -0.4% | -1.1% | -16.9% |
Recent Filings
8-K
Centene Corporation -- 8-K Filing
Centene's Medicaid health benefit ratio of 93.1% demonstrates improved cost management and operational efficiency, indicating stronger profitability in its core business segment.
Apr 28
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CNC's promotion of a long-tenured finance executive to lead innovation signals management confidence in operational efficiency and digital transformation, potentially improving margins and competitive positioning for investors.
Mar 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
The company is redeeming $1 billion of 2027 notes early, reducing debt obligations and likely lowering future interest expenses, signaling financial strength and improved capital management.
Mar 10
8-K · 7.01
! Medium
Centene Corporation -- 8-K 7.01: Regulation FD Disclosure
Centene reaffirms its 2026 GAAP EPS guidance of greater than $1.98 and adjusted EPS guidance exceeding $3.00, maintaining previous projections.
Feb 23
8-K
Centene Corporation -- 8-K Filing
Centene Corporation provided 2026 guidance through a presentation filed as an 8-K, offering investors forward-looking insights into the company's anticipated financial performance.
Feb 6
Data updated apr 25, 2026 2:08am
· Source: massive.com